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The peroxisome proliferator-activated receptor alpha (PPARα) is a ligand-activated transcription factor involved in the regulation
ofavarietyofprocesses,rangingfrominﬂammationandimmunitytonutrientmetabolismandenergyhomeostasis.PPARαserves
as a molecular target for hypolipidemic ﬁbrates drugs which bind the receptor with high aﬃnity. Furthermore, PPARαbinds and is
activatedbynumerousfattyacidsandfattyacid-derivedcompounds.PPARαgovernsbiologicalprocessesbyalteringtheexpression
of a large number of target genes. Accordingly, the speciﬁc role of PPARα is directly related to the biological function of its target
genes. Here, we present an overview of the involvement of PPARα in lipid metabolism and other pathways through a detailed
analysis of the diﬀerent known or putative PPARα target genes. The emphasis is on gene regulation by PPARα in liver although
many of the results likely apply to other organs and tissues as well.
1.Introduction
Nutrient metabolism and energy homeostasis are tightly
controlledbynumerousregulatorysystemsinvolvingspeciﬁc
transcription factors. The peroxisome proliferator-activated
receptors (PPARs) are ligand-activated transcription factors
that belong to the superfamily of nuclear hormone receptors
and play an important role in nutrient homeostasis [1–3].
ThreediﬀerentPPARsubtypesareknown:PPARα,PP ARβ/δ,
and PPARγ. All PPARs share the same molecular mode
of action via formation of heterodimers with the nuclear
receptor RXR, followed by binding to speciﬁc DNA-response
elements in target genes known as peroxisome proliferator
response elements (PPREs). PPREs are characterized by a
common core sequence consisting of a direct repeat of
the consensus sequence AGGTCA interspaced by a single
nucleotide [1, 4]. Expression of PPARα and PPARβ/δ is
found ubiquitously, whereas PPARγ is mainly expressed in
adipose tissue, macrophages, and colon [5, 6]. Activation
of transcription by PPARs is dependent on a number of
diﬀerent steps including ligand binding to PPAR, binding
of PPAR to the target gene, removal of corepressors and
recruitment of coactivators, remodeling of the chromatin
structure, and ﬁnally facilitation of gene transcription [7].
This paper will focus exclusively on PPARα.
PPARα was ﬁrst discovered in the early 1990s and since
then has been identiﬁed as the master regulator of hepatic
lipid metabolism [8]. In addition, PPARα has been shown
to govern glucose metabolism, lipoprotein metabolism,
liver inﬂammation, amino acid metabolism, and hepatocyte
proliferation (speciﬁcally in rodents). Synthetic agonists of
PPARα lower plasma triglycerides and raise plasma high-
density lipoprotein (HDL) levels and are thus used clinically
in the treatment of dyslipidemia [2, 9–11].
In recent years, the advent of microarray technology
has allowed the study of whole genome expression proﬁles.
Accordingly, a wealth of new information has become
available about the role of speciﬁc transcription factors in
regulation of gene expression. Combined with data collected
using more established methods, microarray has permitted
the generation of a comprehensive picture of the impact of
PPARα on gene expression, thereby providing key insight
intothefunctionalroleofPPARα.Thepresentpaperisaimed
at providing a detailed and updated overview of PPARα2 PPAR Research
target genes in diﬀerent biological processes and to highlight
possible diﬀerences between mouse and human.
Although the presence of a functional PPRE is often used
asacriteriafordesignatingdirectPPARαtargetgenes,wedid
not apply this criteria very stringently in our analysis as the
in vivo functionality of most of the identiﬁed PPREs remains
uncertain.Recentstudiesindicatethatthestandardapproach
to screen for PPREs in the 1-2kb region upstream of the
transcriptional start site (TSS) is at odds with accumulating
evidence that PPARs often bind quite distant from the TSS
[12–14]. In those cases, contact with the basal transcription
machinery is expected to be established via DNA looping.
Thus, the absence of a PPRE in the 1-2kb region upstream
of the TSS cannot be used as a criterion to disqualify
target genes. Other aspects that need to be taken into
account include correspondence in gene function with better
established PPAR targets and the timing of gene induction
following PPARα activation.
2. PPARα Tissue ExpressionProﬁle in
Mouse and Human
High expression levels of PPARα expression are found in
liver and speciﬁcally in the parenchymal cell population.
Expression of PPARα in nonparenchymal liver cells such as
Kupﬀer cells is much lower [15, 16]. Other tissues with high
PPARα mRNA levels are heart, kidney, intestine, and brown
adipose tissue, all of which are characterized by an elevated
rate of fatty acid catabolism [17]. PPARα expression has
also been detected in immune cells such as the peripheral
blood mononuclear cell population, and speciﬁcally in T-
cells and macrophages [18–22]. Evidence suggests that mice
and humans share similar PPARα tissue expression proﬁles
[6, 17]( Figure 1). In the past, the importance of PPARα
in human liver was questioned based on data showing
approximately 10-fold lower PPARα mRNA levels in human
liver compared with mouse liver [23] .Ar e c e n ts t u d y
using more advanced methodology revealed similar PPARα
expression in mouse and human liver and in mouse and
humanhepatocytes,thusstronglyarguingagainstthisnotion
[24]. Given that PPARα has been most extensively studied
in liver, most of the information on PPARα target genes
presented here relates to hepatic gene regulation.
3. PPARα StructureinMouse andHuman
Analogous to other nuclear receptor superfamily members,
PPARα has a domain structure consisting of an N-terminal
activatingfunction-1(AF-1)domain,acentralDNA-binding
domain (DBD), and a C-terminal ligand-binding domain
(LBD) [25, 26]. The N-terminal domain can be phosphory-
lated leading to changes in transcriptional activity and even
ligand binding of the receptor [27]. The DBD is responsible
for physical interaction with DNA and allows PPARα to bind
to speciﬁc PPREs as a heterodimer with RXR [28]. The LBD
harbors the ligand-binding pocket crucial for dimerization
with RXR and contains the activating function-2 involved in
physical interactions with coregulatory proteins [7, 29, 30].
Comparison of human and murine PPARα shows 85%
identity atthe nucleotide leveland91% identity atthe amino
acid level. Data have indicated that there is some genetic
heterogeneity in the functional coding sequence of human
PPARα that translates into functional diﬀerences in receptor
activity. One identiﬁed variant of the human PPARα gene
produces a protein that is mutated within the PPARα DNA-
binding domain. This L162V gene variant exhibits greater
ligand-induced activity compared to the wild-type receptor
[31, 32]. While there is some evidence for a link between
the L162V polymorphism and metabolic parameters such as
plasma lipid levels, these correlations are not always found
[32–37].Interestingly,theeﬀectofL162Vpolymorphismhas
been suggested to be modulated via gene-drug and gene-
nutrient interactions [38–40]. The V227A polymorphism
was found in Japanese population and has been associated
with altered serum lipid levels and nonalcoholic fatty liver
disease [41–44]. In addition to polymorphic variants, a
truncatedsplice variant of human PPARα hasbeendescribed
that negatively interferes with wild-type PPARα activity [45].
4. PPARα Ligands
PPARα serves as receptor for a structurally diverse set of
compounds. The most important class of synthetic PPARα
ligands is the ﬁbrates, including gemﬁbrozil, bezaﬁbrate,
cloﬁbrate, fenoﬁbrate, and Wy14643 [2, 9–11, 46]. This class
of drugs is used in the treatment of dyslipidemia primarily
associated with type 2 diabetes mellitus. In addition, PPARα
is activated by plasticizers, insecticides, and other rodent
hepatic carcinogens. Natural ligands of PPARα include a
varietyoffattyacidsaswellasnumerousfattyacidderivatives
and compounds showing structural resemblance to fatty
acids, including acyl-CoAs, oxidized fatty acids, eicosanoids,
endocannabinoids, and phytanic acid [47–53]. Endogenous
ligand activation of PPARα in liver was initially suggested
to occur primarily during fasting as large amounts of free
fatty acids are released into the bloodstream and enter the
liver [54, 55]. However, compelling evidence indicates that
hepatic PPARα is not activated by plasma free fatty acids,
whereas it can be activated by dietary fatty acids and fatty
acids generated via de novo lipogenesis [56–60]. Recently, it
was shown that the eﬀects of dietary unsaturated fatty acids
on hepatic gene expression are almost exclusively mediated
by PPARα and mimic the eﬀect of synthetic PPARα agonists
[61].
5. PPARα andHepaticLipidMetabolism
Regulation of lipid metabolism is mainly coordinated by
liver, which actively metabolizes fatty acids as fuel and con-
tinuously produces very low-density lipoproteins (VLDLs)
particlestoprovideaconstantsupplyoffattyacidstoperiph-
eral tissues. Disturbances in these pathways are the basis for
hepatic steatosis and alterations in plasma lipoprotein levels.
Many aspects of hepatic lipid metabolism are under control
of PPARα, including fatty acid uptake through membranes,
fatty acid activation, intracellular fatty acid traﬃcking, fattyPPAR Research 3
Table 1: List of PPARα target genes in diﬀerent biological processes in liver. Genes regulated by PPARα in mouse are shown in lower case.
Genes regulated in human and mouse are shown in CAPITAL BOLD. Genes regulated only in human are shown in CAPITAL, and genes
with detected functional PPRE are shown in italic font.
Lipid
metabolism
Lipid/hormone
transport
Adipor2 [24, 62], Cd36 [24, 62–64], LEPR [24, 62], Slc27a1 [62, 64–67], SLC27A2
[24, 62, 63, 68], SLC27A4 [24, 62]
Acyl-CoA forma-
tion/hydrolysis/
binding
Acot1 [24, 62, 69], Acot7 [62], ACOT12 [24, 62], ACSL1 [24, 62, 70–72], ACSL3 [24, 62],
Acsl4 [24, 62, 63, 73], ACSL5 [24, 62, 63], ACSM3 [24, 62], Acss2 [62], FABP1
[24, 62, 74, 75], Fabp2 [24, 62, 63], FABP3 [24, 62], Fabp4 [62, 68], Fabp5 [62]
Mitochondrial β-
oxidation/oxidative
phosphorylation
ACAA2 [24, 62, 68], Acadl [24, 62, 70, 74, 76], ACADM [24, 55, 62, 70], ACADS
[24, 54, 62, 70], ACADVL [24, 62, 63, 70], Acad8 [62], Acad9 [62], Acad10 [62], Acot2
[24, 62, 69], Acot9 [62], Acot10 [62], CPT1A [24, 54, 55, 62, 77–79], Cpt1b [24, 62],
CPT2 [24, 62, 70, 80], Crat [24, 62, 74], Dci [24, 62, 65, 68, 76], Decr1 [24, 62, 76, 81],
ETFA [24], Etfb [24, 62], ETFDH [24, 62], HADHA [24, 62, 63, 68, 82], HADHB
[24, 62, 63, 68], Hadh [24, 62, 68, 74, 76, 83], Hadh2 [62], Hibch [24, 62], SLC25A20
[24, 62, 84], SLC22A5 [24, 62, 85, 86], TXNIP [24, 62], Ucp2 [24, 62, 87–89], Ucp3 [62]
Ketogenesis/ketolysis Acat1 [24, 62, 68], Bdh [62], FGF21 [24, 62, 90–92], Hmgcl [62], HMGCS2
[24, 62, 93–95]
Peroxisomal
β-oxidation
ABCD2 [24, 62, 96], ABCD3 [24, 62, 96], ACAA1A [24, 62, 68, 76], Acaa1b [24, 62],
Acot3 [24, 62], Acot4 [24, 62], Acot5 [24, 62], Acot8 [62, 97], ACOX1
[24, 55, 62, 68, 70, 98, 99], Crot [24, 62, 74], Decr2 [24, 62, 68, 100] ECH1
[24, 62, 63, 68], Ehhadh [24, 62, 101, 102], HACL1 [24], HSD17B4 [24, 62, 103, 104],
Peci [24, 62, 65, 100], Pex11a [24]
Microsomal
(ω-hydroxylation)
ALDH3A1 [24], Aldh3a2 [24, 62, 105], ALDH9A1 [24], Cyp4a1 [74, 106–109], Cyp4a3
[55, 74, 108], Cyp4a10 [24, 62, 68, 84, 106, 110], Cyp4a12a [24, 62, 65], Cyp4a14
[24, 62, 68, 110, 111], Cyp4f15 [24], Cyp4x1 [24]
Lipogenesis
Acaca [62], ACACB [62], AGPAT2 [62], Agpat3 [24, 62], Agpat5 [62], Agpat6 [62],
Dgat1 [62, 112], ELOVL5 [62, 113, 114], ELOVL6 [24, 62, 113, 114], Elovl7 [62], FADS1
[24, 62, 113], Fads2 [62, 113, 115], Fasn [62, 112], GPAM [24, 62, 65], Hsd17b12 [62],
Lpin2 [24, 56, 62], MLYCD [24, 62], Mogat1 [24, 62], MOD1 [24, 62, 70, 116], Scd1
[24, 62, 117, 118], Scd2 [62, 68], Slc25a10 [62, 100], Srebf1 [24, 62, 119]
Lipases/lipid droplet
proteins
ADFP [24, 62, 120], Ces1 [62], Ces3 [24, 62], Cidea [24, 62, 121], CIDEC [24, 62, 121],
Gos2 [24, 62, 122, 123], Lipa [24, 62], Lipe [24, 62, 68], Mgll [24, 62, 63, 68],
Oxpat/Lsdp5 [24, 62, 124, 125], Plin1 [24], PNPLA2 [24, 62], S3-12 [24, 62]
Lipoprotein uptake
and metabolism
ANGPTL4 [24, 62, 126, 127], APOA1 [128–133], APOA2 [24, 134], APOA5
[24, 135, 136], APOCIII [137–139], LIPC [24, 62], Lipg [62], Lpl [62, 64, 65, 140], Lrp4
[24, 62], PCTP [24, 62], Pltp [62, 65, 141, 142], Mttp [24, 62, 143], VLDLR [24, 62]
Cholesterol/Bile
transport and
metabolism
ABCA1 [24, 62, 144], ABCB4 [24, 62, 94, 144], Abcb11 [62], Abcg5 [62, 144], Abcg8
[62, 144], Cav1 [24], CYP7A1 [24, 62, 145–147], Cyp8b1 [62, 148], Cyp27a1 [145], FXR
[62], LXR [144, 149], Npc1 [62], Rab9 [24, 62], Scarb2 [62], Slc10a1 [94], Slc10a2
[62, 150]
Other pathways
Glucose/Glycerol
transport and
metabolism
AQP3 [24, 62, 151], Aqp7 [62], Aqp9 [62, 151], Fbp2 [24, 62], G6PC [24], Gpd1
[24, 62, 151], Gpd2 [62, 151], GYK [24, 62, 151], Gys-2 [152], Ldha [62], Pcx [62], PCK1
[24], Pdk1 [24], PDK4 [24, 62, 153, 154]
Biotransformation
AKR1B10 [24], AKR1C3 [24], CYP1A2 [24], Cyp2a5 [110], CYP2B6 [24], CYP2C8 [24],
CYP2C9 [24], Cyp2c11 [155], Cyp2c12 [155], Cyp2c29 [110], CYP2J2 [24], CYP3A5
[24], CYP3A7 [24], CYP3A11 [24, 110], Cyp3a43 [24], EPHX2 [24, 156], Gsta3 [157],
MGST3 [24], UGT1A9 [158]
Amino Acid
metabolism
ABAT [24, 159], Acmsd [159], AGXT2 [24, 160], Arg1 [160], ASL [24, 160], Ass1 [160],
CBS [24, 159], CPS-1 [24, 160], Cth [159], Got1 [160], Got2 [62, 64, 160, 161], Gls
[160], GLS2 [159], GPT [24, 159], Hal [159], Hpd [159], OAT [24, 159], ODC1
[24, 62, 159], OTC [24, 62, 160], PAH [24, 159], PSAT1 [24, 62, 159], Tat [159, 162]
Inﬂammation
Apcs [163], Birc3 [163], Cebpb [164], Cd68 [24, 165], Crp [24, 163], Cxcl10/IP10 [165],
FGB [24, 155, 166, 167], Emr1 (F4/80) [156], Icam-1 [24, 165], Iﬁ47 [24, 163], Igtp
[163], Nfkbia [168–170], Il-1β [165], Il-1r1 [111], Il1rn [163], Il1rap [163], Il-6
[111, 171], Il-6ra [111, 163], Il18 [163], Lcn2 [163, 165], Lifr [163], Ccl2 [165], Ccl3
[165], Mt1 [24, 163], Mt2 [163, 165], Orm2 [163], Orm3 [24, 163], Nfkb1 [24, 164],
Pla1a [24, 163], Saa2 [163], Saa4 [24, 163], Stat1 [165], Stat2 [163], Stat3 [163], Steap4
[24, 163], Stress induced protein [163], Tnfα [165], Traf2 [163], Vcam-1 [24, 165]4 PPAR Research
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Figure 1: Expression proﬁle of PPARαin human tissues. The FirstChoice Human Total RNA Survey Panel (Ambion) was reverse transcribed
and used for qPCR using primers speciﬁc for human PPARα. Expression levels are expressed relative to small intestine, which showed the
highest expression level (100%).
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Figure 2: Schematic representation of PPARα target genes in diﬀerent aspects of hepatic lipid metabolism.
acid oxidation and ketogenesis, and triglyceride storage and
lipolysis (Figure 2). It has been suggested that part of the
eﬀect of PPARα on hepatic ketogenesis may be mediated by
induction of the PPARα target ﬁbroblast growth factor 21
[90–92].Adetaileddiscussionofthespeciﬁcgeneswithinthe
various lipid metabolic pathways that are targeted by PPARα
is provided below (Table 1).
5.1. Peroxisomal Fatty Acid β-Oxidation. The ﬁrst link
between PPARα and fatty acid catabolism was established
by the identiﬁcation of the Acyl-CoA oxidase gene, encod-
ing the rate-limiting enzyme in peroxisomal long-chain
fatty acid oxidation, as a direct PPARα target gene [98,
172]. Peroxisomes are known to be involved in many
aspects of lipid metabolism, including synthesis of bile
acids and plasmalogens, synthesis of cholesterol and iso-
prenoids, alpha-oxidation, glyoxylate and H2O2 metabolism,
and beta-oxidation of very-long-straight-chain or branched-
chain acyl-CoAs. The beta-oxidation of straight-chain acyl-
CoAs starts with a reaction catalyzed by acyl-CoA oxi-
dase 1 (Acox1) followed by one of two enzymes car-
rying both enoyl-CoA-hydratase and 3-hydroxyacyl-CoA
dehydrogenase activity (L-bifunctional enzyme, Ehhadh; D-
bifunctional enzyme, Hsd17b4) and ﬁnally peroxisomal 3-
ketoacyl-CoA thiolase (Acaa1a, Acaa1b). All genes men-
tioned above represent PPARα targets [24, 55, 62, 68, 70, 76,
98,99,101–104].Additionally,genesinvolvedinperoxisomal
fattyaciduptake(Abcd2andAbcd3),conversionoffattyacidPPAR Research 5
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Figure 3: Vanin-1 likely represents a direct PPARα target gene. (a) Vnn1 expression in livers of ad libitum fed and 24h fasted wildtype
and PPARα−/− mice. (b) Vnn1 expression in liver, (c) small intestine, and (d) large intestine of wildtype and PPARα−/− mice 6h after
administration of a single oral dose of Wy14643 (4mg), fenoﬁbrate (4mg), and synthetic triglycerides triolein, trilinolein, trilinolenin,
trieicosapentaenoin, or tridocosahexaenoin (400mL). (e) HepG2 cells were transiently transfected with reporters (PPRE)3-TK-LUC or
PPRE-Vnn1-LUC (PPRE present in intron 3-4 of the Vnn1 gene cloned into pGL3-promoter) and PPARα expression plasmid (pSG5). After
transfection, cells were treated with WY14643 (50μM) for 24 hours followed by determination of luciferase and β-galactosidase activities in
the cell lysates. Luciferase activities were normalized to β-galactosidase, and the relative luciferase activity of the cells treated with DMSO
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to acyl-CoA (Crot), and numerous thioesterases (Acots) that
convert acyl-CoAs back to fatty acids have been reported to
be regulated by PPARα [24, 62, 74, 96, 97]. Activation of
PPARα using synthetic agonists is known to cause massive
proliferation of peroxisomes in rodents via induction of a
large set of genes encoding peroxisomal fatty acid oxidation
enzymes, as well as genes involved in peroxisomal biogenesis
(Pex genes). Chronic exposure to these so-called peroxisome
proliferators can also induce liver cancer in rodents [173].
In contrast, activation of PPARα in humans does not
seem to induce hepatocellular carcinomas, suggesting a
species speciﬁc response to PPARα activation. Initially, it
was believed that the diﬀerential response was due to the
lack activation of Acox1 and other peroxisomal genes by
PPARα in humans [71, 174, 175]. However, recent data
indicate that PPARα is able to induce a signiﬁcant number
of genes involved in peroxisomal fatty acid oxidation in
human primary hepatocytes, including Acox1 [24]. Also,
PPARα-mediated induction of the Pex11a gene involved in
peroxisome proliferation is observed in both species [24].
5.2. Mitochondrial Fatty Acid β-Oxidation. The crucial role
of PPARα in mitochondrial fatty acid oxidation is illustrated
by the phenotype of fasted PPARα−/− mice, which exhibit
hypoketonemia, hepatic steatosis, and elevated plasma free
fatty acid levels [54, 55, 176]. It is now evident that virtually
every enzymatic step within the fatty acid oxidative pathway
isundercontrolofPPARα.Speciﬁcally,PPARαinducesgenes
controlling fatty acid import into the mitochondria (Cpt1,
Cpt2, Slc25a20, Slc22a5), as well as the major enzymes
within the β-oxidation pathway, including various acyl-CoA
dehydrogenases (Acad, step 1), mitochondrial trifunctional
enzyme (Hadh, step 2–4), and genes involved in β-oxidation
of unsaturated fatty acid (Dci, Decr) [24, 54, 55, 62, 63, 65,
68, 70, 74, 76–86].
Additionally, synthesis of ketone bodies via mitochon-
drial HMG-CoA synthase (Hmgcs2) and HMG-CoA lyase
(Hmgcl) is governed by PPARα [24, 62, 93–95], as is the
expression of genes encoding electron transferring ﬂavopro-
tein and the corresponding dehydrogenase (Etfa, Etfb, Etfdh)
[24, 62]. The latter proteins mediate the transfer of electrons
from Acyl-CoA dehydrogenases to the membrane-bound
electron transfer ﬂavoprotein ubiquinone oxidoreductase,
allowing further entry into the oxidative phosphorylation
pathway [177, 178]. Finally, PPARα induces uncoupling
proteins Ucp2 and Ucp3, which have been proposed to
functionasanoutwardtransporterofnonesteriﬁedfattyacid
anions from the mitochondrial matrix [24, 62, 87–89].
5.3. Microsomal Fatty Acid ω-Hydroxylation. Cyp4A
enzymes are members of the cytochrome P450 monoxyge-
nase superfamily and catalyze microsomal ω-hydroxylation
of fatty acids [106, 179]. Studies using PPARα−/− mice have
shown that hepatic expression of Cyp4a genes is almost
completely dependent on PPARα (Cyp4a10, Cyp4a12,
Cyp4a14 in mice, Cyp4a1, Cyp4a3 in rat, Cyp4a11 in
human) [55, 62, 74, 84, 106–111]. Furthermore, expression
is extremely sensitive to PPARα ligand activation, indicating
that Cyp4a genes may serve as PPARα marker genes.
Although previous studies performed in human primary
hepatocytes could not show regulation of Cyp4a by human
PPARα, our microarray data revealed signiﬁcant induction
of Cyp4a11 by Wy14643 in primary human hepatocytes
[24, 68, 180, 181]. ω-hydroxylation of saturated and
unsaturated fatty acids may lead to the generation of high-
aﬃnity PPARα ligands, including hydroxyeicosatetraenoic
acids (HETEs), thus creating a positive feedback loop [182].
Alternatively, induction of ω-oxidation by PPARα has been
suggested to promote the degradation of the PPARα agonist
leukotriene B4 as part of a feedback mechanism aimed at
controlling the duration of the inﬂammatory response [53].
5.4. Hepatic Lipogenesis. Whereas PPARα is mostly known
foritsabilitytoinducefattyacidoxidation,growingevidence
points to a role of PPARα in regulation of lipogenesis.
A functional PPRE was identiﬁed in the promoter of a
limited number of lipogenic genes including Δ6 desaturase
(Fads2), malic enzyme (Mod1), phosphatidate phosphatase
(Lpin2), and Δ9 desaturase (Scd1) [56, 115–117]. Gene
expression proﬁling showed that chronic in vivo treatment
of mice with PPARα agonist causes the upregulation of
a large set of lipid biosynthetic genes [62]. However,
regulation is much less pronounced in primary hepatocytes,
suggesting an indirect mechanism. Consistent with this
notion, induction of lipogenic genes by chronic PPARα
activation was completely abolished in SREBP1−/− mice
[183]. The eﬀect of PPARα agonists on SREBP targets has
been attributed to increased activation of SREBP1c via
enhanced proteolytic cleavage [112]. Such a mechanism
may also lead to increased SREBP1 mRNA via an autoloop
regulatory circuit [184]. Alternatively, it is possible that
PPARα is recruited to promoters of SREBP targets and
stimulates SREBP activity [12]. Interestingly, in rat FAO
hepatoma cells, it was found that PPARα activation reduced
expression of lipogenic genes, including Fasn, Gpam, and
SREBP1c, while Insig1 expression was increased by PPARα
[185]. The reason for the discrepancy is not clear.
Incontrasttodenovofattyacidandcholesterolsynthesis,
synthesis of triglycerides may be directly targeted by PPARα.
Several genes within these pathways are upregulated by
PPARα activation, including Gpam, various Agpat genes,
Mogat1, Dgat1, and Lpin2 [24, 62, 65, 112]. Induction of
genes involved in triglyceride synthesis from fatty acids may
reﬂect a broader role of PPARα in the hepatic response to
fasting aimed at neutralizing large amounts of incoming
adipose tissue-derived free fatty acids.
5.5. Fatty Acid Uptake and Binding. Before they can be
metabolized in the liver, fatty acids have to be transferred
across the cell membrane. Several proteins are involved
in fatty acid transport across the plasma membrane, a
number of which carry both fatty acid transporter and acyl-
CoA synthetase activity. Studies have shown that the fatty
acid transport proteins Slc27a1, Slc27a2, and Slc27a4 are
upregulated by PPARα in liver [24, 62, 64–68, 101].PPAR Research 7
Slc27a1 is not expressed and not regulated by PPARα in
isolatedprimaryhepatocytes,suggestingregulationoccursin
liver macrophages (Kupﬀer cells). So far, the only fatty acid
transporter for which a PPAR response element has been
identiﬁed is Slc27a1. PPARα agonists also markedly induce
hepatic expression of the fatty acid transporter/scavenger
receptor Cd36, which is expressed in various liver cell types
[24, 62–64]. Additionally, expression of numerous acyl-
CoA synthetases is induced by PPARα [24, 62, 63, 70–73].
Currently, limited information is available about the cellular
localization and the structure/function relationship of acyl-
CoA synthetase enzyme [186].
T h eF a b pg e n ef a m i l yc o m p r i s eag r o u po fh i g h - a ﬃnity
intracellular fatty acid-binding proteins. Interestingly, Fabp1
was one of the ﬁrst PPARα target genes identiﬁed [74,
75, 187, 188]. Recent studies indicate that Fabp1 may be
involved in partitioning of FA to speciﬁc lipid metabolic
pathways [189]. Other Fabp genes induced by PPARα
activation in mouse liver include Fabp2, Fabp3, Fabp4,
and Fabp5 [24, 62, 63]. Induction of Fabp4 (A-FABP, aP2)
upon PPARα activation likely occurs via its expression in
Kupﬀer cells. Fabp4 expression in hepatocytes is correlated
with acquisition of a steatotic phenotype concurrent with
upregulation of PPARγ mRNA [190].
5.6. Lipases and Lipid Droplet Proteins. PPARα−/− mice
exhibit elevated hepatic TG accumulation, especially under
fasting conditions [54, 191, 192]. Conversely, treatment with
PPARα agonists lowers hepatic triglyceride levels in models
of hepatic steatosis and can prevent the fasting-induced
increase in liver TG [193, 194]. The antisteatotic eﬀect of
PPARαhasmainlybeenattributedtostimulationoffattyacid
oxidation,whichwoulddecreasetheavailabilityoffattyacids
for TG storage.
Recently,hepaticlipiddropletswereshowntobetargeted
by autophagy, which ultimately leads to TG hydrolysis
via lysosomal acid hydrolase (Lipa). Which other lipases
importantly contribute to intracellular lipolysis of hepatic
TG stores remains unclear, but lipases active in adipocytes
likely play a role, including Ces3, Lipe, Pnpla2, Mgll, and
perhaps Pnpla3 [195–200]. With the exception of Pnpla3, all
of the above genes are induced by short-term treatment with
PPARα agonist in mouse hepatocytes. Regulation of Pnpla2
was also observed in human hepatocytes. Pnpla2 and Lipe
were previously classiﬁed as direct target genes of PPARγ in
adiposetissue,suggestingthattheyaredirecttargetofPPARα
as well [201, 202]. Thus, apart from induction of fatty acid
oxidation, PPARα activation may also decrease hepatic TG
storage by stimulating the TG hydrolysis pathway.
Lipid droplets are coated with one or more mem-
bers of the perilipin family of proteins: perilipin (Plin1),
Adrp/adipophilin (Plin2), Tip47 (Plin3), S3-12 (Plin4), and
Oxpat/Lsdp5 (Plin5). Adrp and Lsdp5 have been identiﬁed
as target genes of PPARα in liver [120, 124]. A recent study
suggests that Adrp could serve as potential mediator of the
eﬀect of PPARα on VLDL production. Adrp induction by
PPARα may diminish VLDL production by favoring fatty
acids storage in cytosolic lipid droplets rather than directing
through VLDL assembly [203]. Besides Adrp, expression of
S3-12 and perilipin, which are known as PPARγ target genes
in adipose tissue, is induced by PPARα agonist in human
hepatocytes [24, 204]. Perilipin expression in human liver is
correlated with development of steatotic liver [205].
Two recently identiﬁed lipid droplet-associated proteins
thatarenotpartoftheperilipinfamilyareCidec(FSp27)and
Cidea [206, 207]. Both proteins promote TG accumulation
and are targets of PPARγ in adipocytes [208, 209]. In
addition, they are regulated by PPARα in mouse liver,
although the kinetics of induction of the two genes seems to
be quite diﬀerent [121]. Cidec but not Cidea upregulation
by PPARα agonist could be conﬁrmed in human primary
hepatocytes [24].
Interestingly, the G(0)/G(1) switch gene 2 (G0s2) was
recently identiﬁed as an inhibitor of Pnpla2 activity and
located to lipid droplets in adipocytes stimulated with β-
adrenergic receptor agonist [122]. Previously, G0s2 was
shown to be a direct PPARα target gene in mouse liver and
PPARγ target in adipocytes [123]. Whether G0s2 associates
with lipid droplets in hepatocytes remains to be further
investigated. Similar to the induction of triglyceride synthe-
sis, regulation of numerous lipid droplet proteins by PPARα
reﬂects a broader role of PPARα in the hepatic response
to fasting aimed at deﬂecting large amounts of incoming
adiposetissue-derivedfreefattyacidstowardsstorageinlipid
droplets.
6. PPARα andLipoproteinMetabolism
Clinical studies in humans have provided ample evidence
that ﬁbrate drugs eﬀectively lower fasting plasma triglyc-
erides (TG) and raise plasma HDL [210–213]. At the
molecular level, ﬁbrates act as synthetic agonist for PPARα,
indicating an important role of PPARα in the control of
lipoprotein metabolism. PPARα lowers plasma TG in part by
reducing very low-density lipoprotein (VLDL) production
[194]. Traditionally, this eﬀect of PPARα was ascribed to
induction of genes involved in fatty acid oxidation and
the concomitant reduction in lipid availability for VLDL
production. However, this paper has made it evident that
in addition to its role in fatty acid catabolism, PPARα
inﬂuences multiple aspects of intracellular lipid traﬃcking
andmetabolism,someofwhichmayopposehepaticTGlow-
ering. Furthermore, expression of Mttp, which is involved in
the lipidation of apoB100 to form a nascent VLDL particle, is
positively regulated by PPARα [214]. Thus, the precise target
genes underlying the suppressive eﬀect of PPARα agonist on
hepatic VLDL production remain to be fully elucidated.
In addition to suppressing VLDL production, PPARα
agonists are known to stimulate clearance of TG-rich
lipoproteins [194]. Clearance of TG-rich lipoproteins VLDL
and chylomicrons is mediated by the enzyme lipoprotein
lipase (LPL), which is attached to the capillary endothelium
of muscle and adipose tissue. Expression of Lpl in liver is
restrictedtoKupﬀercellsandupregulatedbyPPARαagonists
[140, 215]. In contrast, no evidence is available indicating
a stimulatory eﬀect of PPARα on Lpl expression in heart8 PPAR Research
and skeletal muscle, which account for the major share
of plasma TG clearance [140, 216]. LPL activity is mostly
regulated posttranslationally via altered secretion from liver
of LPL-modulating factors, including apolipoprotein C-
III (Apoc3), apolipoprotein A-V (Apoa5), Angiopoietin-
like protein 3 (Angptl3), and Angiopoietin-like protein 4
(Angptl4). Firstly, PPARα agonists downregulate the expres-
sion of LPL inhibitor APOC3, supposedly via mechanisms
involving the transcription factors REV-ERBα,HNF4α,o r
FOXO1 [137, 217–219]. Secondly, PPARα agonists increase
hepatic expression and plasma levels of APOA5, which
is a positive regulator of LPL [220]. A functional PPAR
responsive element has been identiﬁed in the promoter of
the human APOA5 gene, classifying APOA5 as a direct
PPARα target gene [135, 136]. Thirdly, PPARα upregulates
hepatic expression and plasma levels of Angptl4, which
acts as inhibitor of LPL activity by converting active LPL
dimers to inactive monomers [126]. The DNA response
element conferring PPAR regulation was located to intron
3 of the Angptl4 gene [127]. Finally, PPARα stimulates
hepaticexpressionoftheVLDLreceptor(Vldlr)[24,62].The
functional signiﬁcance of Vldlr regulation in liver is unclear,
as Vldlr is most highly expressed in adipose tissue, heart, and
skeletal muscle, where it plays an auxiliary role in plasma TG
hydrolysis by LPL. Recently, Vldlr was shown to be under
control of PPARγ in adipocytes [221]. Thus, it appears that
both pro- and antilipolytic pathways are activated by PPARα.
Under conditions of pharmacological PPARα activation, the
prolipolytic actions of PPARα dominate, as illustrated by the
stimulation of plasma TG clearance.
PPARα agonists raise plasma HDL levels in humans,
which is most likely achieved via species speciﬁc mRNA
induction of apolipoprotein A-I (Apoa1) and A-II (Apoa2)
[128, 175, 222–224]. Apoa1 gene expression is not induced
by PPARα in rodents due to the presence of disabling
mutations within the PPAR-response element [129]. In
fact, PPARα activation in mouse downregulates Apoa1
mRNA expression and plasma concentrations through an
indirect pathway involving the PPARα-dependent induction
of the nuclear receptor REV-ERBα, a negative regulator of
transcription [129, 130, 225].
The impact of PPARα in HDL metabolism likely extends
beyond regulation of apolipoproteins. Evidence suggests
that both PPARα and PPARβ/δ stimulate expression of
endothelial lipase (Lipg) in liver [62, 226]. Endothelial lipase
mainly carries phospholipase activity and its overexpression
was shown to signiﬁcantly reduce plasma HDL cholesterol
levels [227–229]. Since Lipg is expressed in endothelial cells,
macrophages, and hepatocytes, regulation of hepatic Lipg by
PPARαandPPARβ/δ maybemediatedbydiﬀerentcelltypes.
In as much as PPARα agonists raise plasma HDL levels, the
physiological relevance of Lipg induction by PPARα remains
to be established.
In our recent publication, the PPARα agonist Wy14643
modestlyinducedhepaticlipase(Lipc)expressioninprimary
human hepatocytes [24]. Hepatic lipase exhibits both phos-
pholipase and triglyceride hydrolase activity and hydrolyzes
triglycerides and phospholipids of chylomicron remnants,
IDL, and HDL [230]. Whether Lipc represents a direct target
gene of PPARα in human remains unclear. Other genes
involved in lipoprotein metabolism that are regulated by
PPARα include phosphatidylcholine transfer protein (Pctp).
Induction of Pctp mRNA by PPARα is conserved in primary
human hepatocytes [24]. Pctp encodes a steroidogenic acute
regulatory-related transfer domain protein that binds with
highaﬃnitytophosphatidylcholines.Inarecentpublication,
a role for Pctp in the metabolic response to PPARα was
proposed [231]. Overall, it is evident that PPARα governs
multiple aspects of plasma lipoprotein metabolism.
7. PPARα and Glucose/Glycerol Metabolism
Although PPARα has mostly been linked to fatty acid
metabolism, studies in mice have yielded considerable
evidence for a role of PPARα in hepatic glucose metabolism.
Indeed, fasted PPARα−/− mice display severe hypoglycemia
[54, 55, 176]. Several mechanisms may account for the hypo-
glycemia, including decreased hepatic glucose production
and increased peripheral glucose utilization. Genes involved
in gluconeogenesis that have been identiﬁed as PPARα
targets include phosphoenolpyruvate carboxykinase (Pck1),
pyruvate carboxylase (Pcx), and lactate dehydrogenase A
[62]. Interestingly, regulation of Pck1 by PPARα was only
observed in human hepatocytes [24]. Pyruvate carboxylase
was identiﬁed as direct target of PPARγ in adipocytes [232].
PPARα was shown to have a speciﬁc role in the metabolic
conversion of glycerol in liver by directly upregulating
expression of genes such as Gpd1, Gpd2, Gyk, Aqp3, and
Aqp9 [151]. Besides governing glucose production, PPARα
may also alter glucose utilization in numerous tissues via
induction of pyruvate dehydrogenase kinase isoform 4
(Pdk4) [153, 154, 233–236]. Pdk4 phosphorylates and inac-
tivates pyruvate dehydrogenase, thereby limiting carbon ﬂux
through glycolysis. Synthesis of glycogen is also aﬀected in
PPARα−/− mice, which may be mediated in part via defective
regulation of Gys2 [152]. It is noteworthy that in contrast
to studies in mice, human trials generally do not support
an eﬀect of PPARα activation on plasma glucose levels.
Consistent with these data, it was found that upregulation of
genes involved in the glycolysis/gluconeogenesis pathway by
Wy14643 was uniquely observed in mouse hepatocytes and
not human hepatocytes [24].
8. PPARα andHepatic
Cholesterol/Bile Metabolism
It has been demonstrated that PPARα activation increases
eﬄux of cholesterol to HDL. Formation of nascent HDL is
mediated by Abca1-dependent lipidation of newly-secreted
Apoa1. Expression of Abca1 is upregulated by PPARα
agonists in both human and mouse hepatocytes, as well as
in mouse intestine [24, 237]. Presently, it is not clear if this
eﬀect of PPARα activation is mediated via LXRα,a sw a s
shownpreviouslyinmacrophages[21].Othergenesinvolved
in cholesterol uptake and transport that were shown to be
under control of PPARα include Abcg5, Abcg8, Cav1, Npc1,
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While PPARα is known to govern speciﬁc genes involved
in bile acid synthesis, the overall impact on bile acid
homeostasis remains somewhat ambiguous. Expression of
Cyp7a1, which represents the rate-limiting enzyme in bile
acid synthesis, is markedly downregulated in PPARα−/− mice
in fasting condition [62]. Paradoxically, synthetic PPARα
agonists reduce Cyp7a1 expression in both mice and human
[145, 238–240]. In agreement with the latter observation,
ﬁbrate treatment leads to decreased bile acid synthesis. To
what extent the changes in Cyp7a1 expression reﬂect direct
regulation by PPARα is unclear as PPARα also inﬂuences
the expression of other nuclear hormone receptors involved
in regulation of Cyp7a1 such as FXR and LXR. It has also
been suggested that PPARα can antagonize LXR signaling
and LXR-dependent activation of Cyp7a1 gene promoter
[241–243].
Other genes involved in bile acid synthesis that are reg-
ulated by PPARα include Cyp27a1 which is downregulated
by PPARα agonists in a PPARα-dependent manner [145],
and Cyp8b1 which is upregulated by PPARα [62, 148].
Recently, CYP7b1 expression was shown to be suppressed
by PPARα in a sex-speciﬁc manner, which was shown
to occur via sumoylation of the LBD of PPARα [244].
Finally, PPARα stimulates expression of the hepatobiliary
phospholipid transporter Abcb4 [24, 62, 94, 144].
9. PPARα andAminoAcidMetabolism
Accumulating evidence supports a role for PPARα in regula-
tionofaminoacidandureametabolism[159,160,162,245].
Studies in mice have shown that PPARα governs metabolism
of amino acids by suppressing expression of genes involved
in transamination (Aspartate amino transferase (Got1),
Alanine amino transferase (Gpt), Alanine glyoxylate amino-
transferase (Agtx2), and deamination (Glutaminase (Gls)),
as well as numerous genes that are part of the urea cycle
(Cps1,Otc,Ass1,andAsl)[160,161,245].Inagreementwith
thesedata,PPARα−/− miceexhibitincreasedplasmaurealev-
els [160]. Several of the above genes were also downregulated
by PPARα agonistin primary humanhepatocytes, suggesting
that regulation of nitrogen metabolism by PPARα is at least
partially conserved between mice and human [24].
At the present time, the mechanism behind downregu-
lation of nitrogen metabolism by PPARα remains elusive. It
has been proposed that PPARα may modulate the activity of
othertranscriptionfactorsthataredirectlyinvolvedinamino
acid homeostasis, including HNF4α and C/EBPα [160].
However, concrete evidence supporting such a mechanism
is lacking.
Whereas PPARα activation decreases hepatic amino-
transferase expression in mice, PPARα agonists were shown
to increase expression of Gpt in human hepatocytes and
HepG2 cells, which occurred via direct regulation of the
gene promoter [161, 246]. The observed increase in plasma
alanine amino transferase activity in patients treated with
ﬁbrates may thus be related to direct regulation of Gpt
transcription, rather than drug-induced liver injury.
10. PPARα and Inﬂammation
Besides regulating numerous metabolic pathways, PPARα
also governs inﬂammatory processes, which is mainly
achieved by downregulating gene expression via a mecha-
nism generally referred to as transrepression. The ﬁrst clue
towards anti-inﬂammatory eﬀects of PPARα came from
the observation that PPARα−/− mice exhibit a prolonged
inﬂammatory response in the ear swelling test [53]. The
anti-inﬂammatory eﬀects of PPARα are likely explained by
interference of PPARα with the activity of many proinﬂam-
matory transcription factors including signal transducer and
activator of transcription (Stat), Activator protein-1 (AP-
1), and NF-κB[ 247]. Speciﬁcally, it has been shown that
activated PPARα binds to c-Jun and to the p65 subunit
of NF-κB, thereby inhibiting AP-1- and NF-κB- mediated
signaling [248]. Additionally, PPARα induces the inhibitory
protein IκBα, which normally retains NF-κB in a nonac-
tive form, leading to suppression of NF-κB DNA-binding
activity [168]. Suppression of ﬁbrinogen gene expression
by PPARα activation is likely mediated by interference with
the transcription factor CAATT/enhancer-binding protein
(C/EBP) via sequestration of the coactivator glucocorticoid
receptor-interacting protein 1/transcriptional intermediary
factor 2 (GRIP1/TIF2) [166]. Finally, recent data indicate
that activated PPARα may downregulate gene expression by
causing the loss of STAT1 and STAT3 binding to DNA [12].
Speciﬁc genes downregulated by PPARα include a num-
ber of acute phase genes such as ﬁbrinogen, serum amyloid
P-component,lipocalin2,metallothioneins,andserumamy-
loid A2, which were shown to be suppressed by the PPARα
agonist Wy14643 in wild-type mice but not PPARα−/− mice
[163]. Similarly, in humans fenoﬁbrate treatment has been
shown to decrease plasma levels of several acute phase
proteins including C-reactive protein, ﬁbrinogen-α and -β
and interleukin 6 [166, 249, 250]. With the exception of the
sIl-1 receptor antagonist and Vanin-1, to our knowledge no
inﬂammatory genes have been identiﬁed as direct positive
targets of PPARα [163].
The Vanin-1 (Vnn1) gene encodes a glycosylphosphati-
dylinositol-linked membrane-associated pantetheinase that
generates cysteamine from pantothenic acid. Studies suggest
that Vanin1 may promote inﬂammation. Mice lacking
Vnn1 showed decreased NSAID- or Schistosoma-induced
intestinal inﬂammation, which was associated with higher
glutathionelevels[251].OtherevidenceindicatesthatVanin-
1 stimulates production of inﬂammatory mediators by
intestinal epithelial cells and thereby controls the innate
immune response, possibly by antagonizing PPARγ activ-
ity [252]. Epithelial Vanin-1 was also found to regu-
late inﬂammation-driven cancer development in a colitis-
associated colon cancer model [253]. Evidence presented in
Figure 3 demonstrates that Vnn1 likely represents a direct
target gene of PPARα. Expression of Vnn1 in mouse liver
was markedly increased by fasting in wildtype but not
PPARα−/− mice (Figure 3(a)). Negligible Vnn1 expression
was detected in PPARα−/− mouse liver. Moreover, hepatic
Vnn1 expression was signiﬁcantly induced by 6h treatment
with dietary fatty acids and by the synthetic PPARα agonists10 PPAR Research
Wy14643 and fenoﬁbrate (Figure 3(b)). Additional data lend
strong support to the importance of PPARα in Vnn1 gene
regulation in small and large intestine (Figures 3(c) and
3(d)), although the results are not quite as striking as in
liver. Finally, it was shown that two adjacent and partially
overlapping PPREs located around 4kb downstream of
the transcription start site of the mouse Vnn1 gene were
functional in a luciferase reporter assay in HepG2 cells
(Figure 3(e)). PPARα transfection and Wy14643 markedly
increasedluciferaseactivity,althoughforreasonsthatremain
unclear, no synergism between the two treatments was
observed. Overall, these data suggest that Vnn1 represents a
direct PPARα target gene.
TheabilityofPPARαtostimulatefattyacidoxidationand
suppress hepatic inﬂammation has led to the exploration of
PPARα agonists as a therapeutic option for nonalcohol fatty
liver disease and speciﬁcally nonalcoholic steatohepatitis
(NASH). Several studies in mice have shown that PPARα
activation can reduce or even reverse the progression of
steatohepatitis [193, 254–259]. The inhibitory eﬀect of
PPARα on progression of steatosis to steatohepatitis may
be mediated in part by COX2 (Ptgs2), a candidate gene
involved in steatohepatitis development that is suppressed
by PPARα [260]. In the absence of PPARα, liver steatosis
and inﬂammation are enhanced in mice chronically fed a
HFD [165]. Whether the eﬀects of PPARα on NASH are
primarily related to changes in hepatic TG content or occur
via direct suppression of inﬂammatory genes and markers
remains unclear.
11. PPARα and Biotransformation
The detoxiﬁcation of endogenous and exogenous molecules
is generally divided into three distinct biotransformation
phases. The phase I reaction involves the introduction of a
polar group into the xenobiotic molecule and is catalyzed
by members of the cytochrome P450 (CYP) superfamily
[179,180,261].PhaseIIenzymesareresponsibleforcovalent
linkage of the absorbed chemicals or products of the phase I
reactions with compounds such as glutathione, glucuronic
acid, or amino acids and are carried out by sulfotrans-
ferases, UDP-glucuronosyltransferases (UGTs), glutathione-
S-transferases (GSTs), and N-acetyltransferases [261]. The
third phase corresponds to elimination of the conjugated
molecule from cells and their excretion into bile or urine
via speciﬁc transporters, mainly members of the superfam-
ily ATP-binding cassette transporter proteins [262, 263].
Studies have shown that peroxisome proliferators modulate
exclusively the Cyp4a class of monooxygenases (involved in
the metabolism of biologically important compounds such
as fatty acids, see Section 5.3) in mouse while regulating
various other Cyp genes in human hepatocytes, including
membersoftheCyp1a,Cyp2a,Cyp2c,andCyp2esubfamilies
[24]. Our recent microarray data conﬁrmed the human
speciﬁc regulation of Cyp genes belonging to classes 1-3
by PPARα in primary human hepatocytes. Interestingly, we
also observed a signiﬁcant induction of another subfamily
member of Cyp4 enzymes, Cyp4x1, by PPARα in human
primary hepatocytes which was not conserved in mouse
[24]. Cyp4x1 has been shown to be involved in oxidation of
anandamide, which represents one of the endocannabinoids.
Besides upregulation of gene expression, a number of genes
involved in phase I biotransformation are downregulated by
PPARα in mice, including Cyp2a5, Cyp2c11, Cup2c12, and
Cyp2c29 [110, 155].
With respect to phase II biotransformation, PPARα has
been shown to downregulate Glutathione-S-transferase A
[GSTA], possibly leading to decreased biliary excretion of
glutathione conjugates [157, 264, 265]. In contrast, expres-
sion of UDP-glucuronosyltransferase 1A (Ugt1a9), which
participates with other UGT enzymes in glucuronidation
of bilirubin, arachidonic, and linoleic acid metabolites, is
under direct stimulatory control of PPARα [158]. Overall,
it is evident that PPARα is a major regulator of biotrans-
formation enzymes and governs the expression of numerous
cytochrome P-450 and conjugating enzymes. However, only
a small portion of the regulation seems to be conserved
between rodents and humans.
12. Conclusion
In 2010, we are celebrating the 20th anniversary of the
discovery of PPARα by Isseman and Green. PPARα was
initially isolated as a novel nuclear hormone receptor that
serves as molecular target of a diverse class of rodent hepato-
carcinogens. Since then it has become clear that PPARα can
be activated by a large variety of endogenous and synthetic
agonists including ﬁbrate drugs. In fact, PPARα is nowadays
considered as a crucial fatty acids sensor that mediates the
eﬀects of numerous fatty acids and fatty acid derivatives
on gene expression. Furthermore, over the years PPARα has
emerged as a crucial transcriptional regulator of numerous
metabolic and inﬂammatory processes.AlthoughPPARα has
mostly been connected with stimulation of fatty acid oxida-
tion, it is now evident that the eﬀects of PPARα are much
more widespread and cover numerous aspects of nutrient
metabolism and energy homeostasis, including metabolism
of lipoproteins, glucose/glycerol, cholesterol and bile acids,
xenobiotics, and amino acids. Certainly, PPARα merits the
classiﬁcation as a master regulator of hepatic intermediary
metabolism. Until recently, much confusion surrounded the
eﬀects of PPARα activation in human liver. Recent studies
indicate that at least in terms of lipid metabolism, the
function and speciﬁc target genes of PPARα are generally
wellconservedbetweenmouseandhuman.Oneofthemajor
challenges lying ahead is to gain better understanding of the
molecular mechanism underlying downregulation of gene
expression by PPARα, to improve insight into the speciﬁc
mechanisms and pathways of endogenous PPARα activation,
and to better link the functional consequences of PPARα
activation to induction of speciﬁc PPARα target genes.
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